Nanomedicine News

RSS

Seventh U.S. Patent for Nanoemulsion Technology Awarded to NanoBio

NanoBio Corporation announced today that it has been awarded a seventh U.S. patent covering its novel nanoemulsion technology.

From BlueWillow Biologics 4 Aug 2010

Molecule-Sized Nanofibers to Mimic Structure of White Matter in the Brain

Cancer and engineering scientists at The Ohio State University are collaborating to create molecule-sized nanofibers to mimic the structure of white matter in the brain. By combining nanotechnology with a medically-appro...

3 Aug 2010

NanoKTN and IoN Collaborate to Support UK Nanotechnology SMEs

The Nanotechnology Knowledge Transfer Network (NanoKTN), one of the UK's primary knowledge-based networks for micro and nanotechnologies, has announced a collaboration with the Institute of Nanotechnology (IoN), a pr...

3 Aug 2010

New Study Shows How Bee Venom Peptides Deliver Liposomal Nanoparticles to Target Tumor Cells

The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to t...

3 Aug 2010

Researchers Demonstrate How Iron Oxide Nanoparticles Aid Tumor Treatment

Tiny particles of iron oxide could become tools for simultaneous tumor imaging and treatment, because of their magnetic properties and toxic effects against brain cancer cells. In mice, researchers from Emory University School of Medicine have demonstrated how these particles can deliver antibodies to implanted brain tumors, while enhancing tumor visibility via magnetic resonance imaging (MRI).

3 Aug 2010

Scientists Design Nanoparticle for microRNA Delivery

Researchers at the University of California, San Diego School of Medicine have identified a new way to regulate the uncontrolled growth of blood vessels, a major problem in a broad range of diseases and conditions. Th...

2 Aug 2010

MEDSAFE Approves Marketing of ABRAXANE for Metastatic Breast Cancer Treatment

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

30 Jul 2010